ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Huang et al. found that the Beclin1 directly interacts with BCR/ABL and overexpression of BECLIN1 could be promising via BCR/ABL degradation in LCS-CML cells of patient's resistant to TKI(37).